ESMO 2021, News
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
Your search for non small cell lung cancer returned 53 results
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
ATS 2022
Predicting Lung Cancer: Risk-Based LDCT Screening vs Age and Pack-Years
Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?
Drugs in the Pipeline
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Drugs in the Pipeline
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
News
FDA Panel Rejects Lilly Cancer Drug Tested Only in China
Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer
News
Cemiplimab Application for Advanced Cervical Cancer Withdrawn
The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.
News
Lung Cancer Treatment May Impact Daily Function in Older Adults
Life-space assessments may help older adults better understand how cancer treatment impacts their lives, authors say
Drugs in the Pipeline
Improved Overall Survival With Cemiplimab in Cervical Cancer Trial
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
